Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Pfizer (PFE) is a leading drug manufacturers-general business based in the US. It opened the day at $43.91 after a previous close of $44.16. During the day the price has varied from a low of $43.52 to a high of $43.94. The latest price was $43.52 (25 minute delay). Pfizer is listed on the NYSE and employs 79,000 staff. All prices are listed in US Dollars.
Finder Award
SoFi Invest
Robinhood
tastyworks
| Open | $43.91 |
|---|---|
| High | $43.94 |
| Low | $43.52 |
| Close | $43.52 |
| Previous close | $44.16 |
| Change | $-0.64 |
| Change % | -1.445% |
| Volume | 1,006,590 |
| 52-week range | $41.09 - $54.96 |
|---|---|
| 50-day moving average | $49.54 |
| 200-day moving average | $48.98 |
| Wall St. target price | $55.20 |
| PE ratio | 8.5651 |
| Dividend yield | $1.59 (3.65%) |
| Earnings per share (TTM) | $5.22 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $43.5219 from 2023-01-31
| 1 week (2023-01-25) | -3.43% |
|---|---|
| 1 month (2022-12-30) | -15.06% |
| 3 months (2022-11-01) | -9.35% |
| 6 months (2022-08-01) | -14.01% |
| 1 year (2022-02-01) | -17.99% |
|---|---|
| 2 years (2021-02-01) | 21.57% |
| 3 years (2020-01-31) | 23.37% |
| 5 years (2018-02-01) | 24.74% |
Valuing Pfizer stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pfizer's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pfizer's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Pfizer shares trade at around 9x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Pfizer's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1729. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Pfizer's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Pfizer's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $44.8 billion.
The EBITDA is a measure of a Pfizer's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $99.9 billion |
|---|---|
| Operating margin TTM | 39.96% |
| Gross profit TTM | $50.6 billion |
| Return on assets TTM | 13.32% |
| Return on equity TTM | 35.51% |
| Profit margin | 29.81% |
| Book value | $16.51 |
| Market capitalisation | $251 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Pfizer.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 33.15
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Pfizer's overall score of 33.15 (as at 12/31/2018) is pretty weak – landing it in it in the 60th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Pfizer is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 7/100
Pfizer's environmental score of 7 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Pfizer is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 18.47/100
Pfizer's social score of 18.47 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Pfizer is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 13.68/100
Pfizer's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Pfizer is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Pfizer scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Pfizer hasn't always managed to keep its nose clean.
Pfizer Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 33.15 |
|---|---|
| Total ESG percentile | 60 |
| Environmental score | 7 |
| Environmental score percentile | 6 |
| Social score | 18.47 |
| Social score percentile | 6 |
| Governance score | 13.68 |
| Governance score percentile | 6 |
| Level of controversy | 3 |
Dividend payout ratio: 24.69% of net profits
Recently Pfizer has paid out, on average, around 24.69% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.65% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Pfizer shareholders could enjoy a 3.65% return on their shares, in the form of dividend payments. In Pfizer's case, that would currently equate to about $1.59 per share.
While Pfizer's payout ratio might seem low, this can signify that Pfizer is investing more in its future growth.
Pfizer's most recent dividend payout was on 2 March 2023. The latest dividend was paid out to all shareholders who bought their shares by 25 January 2023 (the "ex-dividend date").
Pfizer's shares were split on a 1054:1000 basis on 16 November 2020. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1054 shares. This wouldn't directly have changed the overall worth of your Pfizer shares – just the quantity. However, indirectly, the new 5.1% lower share price could have impacted the market appetite for Pfizer shares which in turn could have impacted Pfizer's share price.
Over the last 12 months, Pfizer's shares have ranged in value from as little as $41.0928 up to $54.9632. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Pfizer's is 0.6331. This would suggest that Pfizer's shares are less volatile than average (for this exchange).
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.